Objective: HIV-related renal dysfunction is associated with high mortality. Data on the prevalence of renal dysfunction among HIV-infected outpatients starting antiretroviral therapy (ART) in sub-Saharan Africa are limited. Recent recommendations to include the nephrotoxic drug tenofovir in first-line ART regimens make clarification of this issue urgent.
Introduction
HIV infection and HIV-induced inflammation can cause chronic kidney disease (CKD), which is associated with increased mortality [1, 2] . The occurrence of renal dysfunction in the HIV-infected population may be further increased by drug-induced renal toxicity, opportunistic infections, and comorbid diseases including hypertension, diabetes, and hepatitis C. With the inclusion of tenofovir in first-line antiretroviral therapy (ART) regimens recommended by the WHO, risk for renal dysfunction in HIV-positive patients may continue to rise.
Early diagnosis and regular monitoring for renal dysfunction in HIV-positive patients is essential for prognosis, medication dosing, and treatment. The risk of undiagnosed HIV-associated renal dysfunction is worrisome in resource-limited settings in which routine laboratory testing is often not available. The WHO recommends assessing creatinine clearance for patients at initiation of tenofovir and every 6 months 'if feasible', though inability to test does not preclude tenofovir use [3] . In high-resource countries, renal monitoring is recommended at HIV diagnosis and at least yearly thereafter for patients with CKD risk factors including African ethnicity, CD4 þ T-cell (CD4) count below 200 cells/ml, or plasma viral load above 4000 copies/ml [4] [5] [6] . In sub-Saharan Africa, screening may be even more urgent because many patients have all of these risk factors, often first presenting for care when they already have low CD4 cell counts and high viral loads.
Despite the high risk for renal dysfunction among HIVinfected patients from sub-Saharan Africa, it has been studied relatively infrequently in this population. In particular, the prevalence of microalbuminuria, which has recently been associated with increased mortality [7] , has received little attention. For this reason, we explored markers of renal dysfunction as measured by serum creatinine, estimated glomerular filtration rate (eGFR), proteinuria, and microalbuminuria in a cohort of Tanzanian outpatients initiating ART.
Methods

Trial design and study participants
The cross-sectional study was conducted in the outpatient HIV clinic at Bugando Medical Centre in Mwanza, Tanzania, between November 2009 and February 2010. Bugando is the regional referral hospital that serves approximately 13 million people in the Lake Victoria region of northwest Tanzania. Over 4000 outpatients are currently on ART at Bugando's HIV clinic.
Patients who were at least 18 years old, were ART-naive, and had been referred for counseling to initiate ARTwere consecutively invited to participate. Patients with risk factors for renal disease including hepatitis B or C virus coinfections, hypertension, hyperglycemia, pregnancy, or febrile illness were excluded. Patients who provided written informed consent underwent structured interviews, physical examinations, and laboratory testing. This study was approved by the joint research ethics committee of Bugando Medical Centre and Weill-Bugando University College of Health Sciences and by Weill Cornell Medical College's Institutional Review Board.
Clinical and laboratory assessment
Physical examinations included two blood pressure readings and height and weight measurements for BMI calculations. Random blood glucose was measured by fingerstick. Patients with glucose levels higher than 7.0 mmol/l (126 mg/dl) were excluded.
Urine samples were measured for proteinuria using urine dipstick Multistix (Bayer, Germany) and for microalbuminuria using Micral-TestB immunoassay (Boehringer-Mannheim, Germany). Proteinuria was reported as negative, 1þ (30 mg/dl), 2þ (100 mg/dl), 3þ (300 mg/dl), or 4þ (1000 mg/dl). Microalbuminuria was reported as negative, 20, 50, and 100 mg/l. A reading of 20 mg/l or higher was considered positive, in accordance with the manufacturer's recommendations.
Blood samples were analyzed for hepatitis B surface antigen and hepatitis C antibody by One-Step Ultra rapid chromatographic and Hepatitis C Virus Rapid Test Strip immunoassays, respectively (Acon Laboratories, California). Serum creatinine and hemoglobin are routinely measured for patients initiating ART. We calculated eGFRs using the Cockroft-Gault and the Modification of Diet in Renal Disease (MDRD) formulae, and normalized the Cockroft-Gault result for body surface area so that results of both equations were in units of ml/ min per m 2 , as previously described [8] .
Renal dysfunction was graded from 0-5 according to the National Kidney Foundation guidelines (Table 1) [9] .
Statistical analysis
Data were analyzed using STATA 11 (College Station, Texas). Continuous data were described as means (AE SDs) and compared by Student's t-test. Categorical data were described as proportions and analyzed using chi-squared or Fisher's exact test. Univariate followed by multivariate logistic regression analyses were performed using Pearson's correlation coefficient to determine predictors of eGFR below 60 ml/min per 1.73 m 2 .
Results
Patient characteristics
Of 418 HIV-infected patients starting ART at Bugando, 355 (85%) were eligible and provided informed consent.
Sixty-three patients were excluded for the following reasons: hepatitis B co-infection (30), pregnancy (15) , febrile illness (9), lost to follow-up (4), hypertension (3), and hepatitis C coinfection (2) . Patients were 65% women, with a mean age AESD of 36.1 AE7.9 years. The mean BMI was 21.3 AE 3.8 kg/m 2 , and the mean CD4 cell count was 141 AE 90 cells/ml.
Prevalence of markers of renal dysfunction
In this population without known pre-existing renal disease or risk factors aside from HIV infection, 85.6% of patients (304 of 355) had evidence of renal dysfunction as defined by an eGFR below 90 ml/min per 1.73 m 2 or an eGFR above 90 ml/min per 1.73 m 2 with proteinuria or microalbuminuria (Table 1 ). If we conservatively consider only patients with eGFRs below 90 ml/min per 1.73 m 2 , renal dysfunction affected 63.7% (226 of 355). Overall, 137 (38.6%) had eGFRs of 60-89 ml/min per 1.73 m 2 , and 87 (24.5%) had eGFRs of 30-59 ml/min per 1.73 m 2 . The prevalence of microalbuminuria was 72.1%, and 36.3% had proteinuria. Microalbuminuria was significantly more common in women (75.3 versus 65.3%, P ¼ 0.047), but not in patients with BMIs less than 18.5 kg/m 2 (67.1 versus 73.3%, P ¼ 0.30).
Predictors of moderate-to-severe renal dysfunction By both univariate and multivariate analysis, significant predictors of moderate or severe renal dysfunction (eGFR <60 ml/min per 1.73 m 2 ) included: female sex, BMI less than 18.5 kg/m 2 , CD4 cell count below 200 cells/ml, and symptomatic HIV infection (WHO stage II, III, or IV disease) ( Table 2 ). Age and clinical signs including wasting, flank pain, edema, and anemia were not predictive of renal dysfunction.
Assessment of Cockroft-Gault and Modification of Diet in Renal Disease Equations
We also calculated eGFR by MDRD equation, which has been adapted for use in North American populations, including African-Americans. The prevalence of abnormal eGFR below 90 ml/min per 1.73 m 2 remained approximately 60% regardless of which equation was used ( Table 1 ).
Discussion
Over 80% of HIV-infected patients starting ART in our setting in Tanzania had evidence of renal dysfunction, with reduced eGFR in over 60% of patients screened. These patients had no known pre-existing renal disease or risk factors for renal dysfunction apart from HIV infection. These high rates of renal dysfunction were confirmed by the finding that over 70% of patients had detectable microalbuminuria. To the best of our knowledge this is the first large HIV-positive African cohort HIV-associated renal dysfunction Msango et al. 1423 in which microalbuminuria, often the first marker of renal disease, has been measured in all study participants. The finding that renal dysfunction may be present in the majority of HIV-infected outpatients initiating ART has important ramifications given the increasingly widespread use of tenofovir, a first-line agent recommended by the WHO with known renal toxicity.
Our data suggest that the low eGFRs that we observed reflect true renal disease because patients with lower eGFRs were also more likely to have microalbuminuria. A single measurement showing microalbuminuria has recently been associated with increased mortality in HIV-infected women [7] . We observed mostly mild to moderate microalbuminuria (20-50 mg/dl), rather than overt proteinuria (>100 mg/dl). This may reflect earlystage, rather than advanced, renal dysfunction. Factors highly predictive of renal dysfunction included female sex and BMI less than 18.5 kg/m 2 , in addition to previously described risk factors of low CD4 cell count and advanced WHO clinical stage [10, 11] . Microalbuminuria was also more common among women, supporting our finding that female sex is associated renal dysfunction.
The 25% prevalence of at least moderate renal dysfunction (eGFR <60 ml/min per 1.73 m 2 ) in our cohort is among the highest reported from sub-Saharan Africa. In a cohort of Ugandan outpatients initiating ART, the prevalence was 42% [12] . Rates have been lower in other HIV-positive, ART-naive outpatients in sub-Saharan countries: 8% in Zambia [13] , 7% in the DART study (Uganda/Zimbabwe) [10] , and 12% in Kenya [11] . Apart from the Kenyan study in which patients had less advanced disease, patients in the other studies had mean BMIs and CD4 cell counts comparable to or lower than ours, and sex distributions were similar.
Our study was conducted in the Lake Victoria region, where both Schistosoma haematobium and mansoni are endemic. Schistosomiasis is associated with cystitis, obstructive uropathy, and immune-mediated glomerulonephritis, and may have contributed to the prevalent renal dysfunction we observed. Resources did not permit performance of diagnostic renal biopsies, but HIVassociated nephropathy (HIVAN) may also be prevalent in our setting. Although not well studied in sub-Saharan Africa, development of HIVAN may depend on genetic factors and prevalence appears to vary even within countries [14] [15] [16] [17] [18] so this could be another explanation for differences between our findings and that of others.
Depending on cause, ART may improve or further impair renal function [12, 19] . Regardless of cause, our study reinforces the importance of monitoring renal function before initiating and while using ART in HIVinfected individuals in sub-Saharan Africa.
We observed some variation between GFRs estimated by the Cockroft-Gault and MDRD equations, with lower GFRs estimated by Cockroft-Gault. This is consistent with other studies from East Africa [8, 11] . It has been suggested that this discrepancy is caused by an MDRD adjustment for black race that is too high for East Africans [8] . The MDRD equation was derived in the US, where most black patients in the derivation cohort were likely of West African descent. For optimal individual patient management, the discrepancies observed underscore the need for additional studies to clarify which eGFR equation is most accurate in East African populations. From a public health perspective, the high prevalence of renal dysfunction in our patients is notable and consistent regardless of which formula was used.
Clinically, the high rates of renal dysfunction we observed are concerning given the WHO's recommendation to use either tenofovir or lamivudine, both of which require dose adjustment in renal dysfunction, in all four first-line ART regimens [3] . Tenofovir can additionally cause new-onset or worsening renal toxicity due to proximal tubular dysfunction [19] [20] [21] [22] , which is not always reversible with tenofovir discontinuation [19] .
On the basis of recommendations to adjust doses for creatinine clearance (CrCl) below 50 ml/min [3, 23, 24] , 51 (14.4%) of the patients in our cohort would have required lower medication doses. Importantly, only 21 of these 51 patients (41.2%) had serum creatinine levels above our laboratory's upper limit of normal (>139 mmol/l) and would have had abnormal renal function identified without calculation of eGFR.
In conclusion, we observed high rates of eGFR impairment in our population of HIV-positive outpatients initiating ART and our findings were corroborated by high rates of microalbuminuria. These results highlight the importance of screening for abnormal eGFR, not merely measuring creatinine, in African HIVinfected patients prior to the initiation of ART for proper dosing of antiretroviral medications. Longitudinal studies are ongoing in our cohort to monitor renal function after ART initiation, to identify other potential contributory factors for renal disease, and to correlate eGFR with true CrCl.
